Elutia Inc. (ELUT) is a Healthcare · Medical Devices company listed on NASDAQ. Price $0.87 (+1.87%), Market cap $0.05B, 52-week low–high $0.51 ~ $2.46.
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconst
Financial statements, price targets, institutional (13F) holdings and related news for Elutia Inc. are updated in real time on BlackAll Trade.
Elutia Inc. trades at $0.87 (+1.87%). Real-time quotes and charts are available on BlackAll Trade.
Elutia Inc. has a market cap of about $0.05B.
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women'